BB Biotech (BION) investor relations material

Executive summary

• Net profit reached CHF 451mn in Q2 2026, reversing a CHF 100mn loss in Q2 2025, driven by disciplined stock selection, clinical execution, and strategic M&A activity.

• NAV rose 17.2% in CHF in Q2 2026, outperforming the Nasdaq Biotechnology Index by 3.5 percentage points; share price returned 9.7% in CHF.

• Twelve new investments diversified the portfolio, and three portfolio companies (Terns Pharmaceuticals, Nuvalent, Crinetics Pharmaceuticals) announced M&A transactions in 2026.

• Outperformance attributed to deliberate portfolio positioning, disciplined stock selection, and enhanced research capabilities, including AI-driven investment processes.

• M&A activity remains strong, with eight acquisitions in the past six quarters, reflecting a significant patent cycle in big pharma.

Financial highlights

• Market capitalization at June 30, 2026: CHF 2,688.5 million; NAV: CHF 3,084.5 million.

• Earnings per share for H1 2026: CHF 7.79 (vs. CHF -6.24 in H1 2025).

• NAV per share at June 30, 2026: CHF 55.95 (up from CHF 50.40 at year-end 2025).

• Total expense ratio (TER) for H1 2026: 1.32% p.a.

• Share price discount to NAV widened to 12.9% as of June 30, 2026.

Outlook and guidance

• The outlook for biotechnology remains constructive, driven by scientific innovation, M&A demand, and large pharma's need for external innovation.

• Disciplined, systematic stock selection emphasized amid elevated near-term uncertainty, including US elections, regulatory changes, and macroeconomic factors.

• Portfolio designed for resilience and long-term value creation, not reliant on market predictions.

• Upcoming regulatory decisions, Phase III data, and M&A transactions expected to provide further value creation opportunities.

• Approximately 7% of NAV is available as cash for future investments.